Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use WINREVAIR safely and effectively. See full prescribing information for WINREVAIR. WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous useInitial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.
- generic_name
- sotatercept-csrk
- brand_name
- water
- product_names
- SOTATERCEPT-CSRK, water
- ndc
- 0006-5090, 0006-5090-01, 0006-5068, 0006-5068-99, 0006-5079, 0006-5079-89, 0006-5091, 0006-5091-01, 0006-5069, 0006-5069-99, 0006-5080, 0006-5080-89, 0006-5087, 0006-5087-01, 0006-5088, 0006-5088-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en